ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Moderate hypofractionation: long-term toxicity results of prostate bed radiotherapy (FRAME-PROSTATE).
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeModerately hypofractionated radiotherapy (m-HRT) is a standard of care in the radical treatment of localized prostate cancer (PCa). Still, its role after radical prostatectomy (RP) is yet to be defined. We present long-term outcome and toxicity results of m-HRT in the post-prostatectomy setting. METHODS AND PATIENTS: Retrospective analysis of 172 PCa patients treated with daily volumetric image-guided Tomotherapy-based m-HRT between 2013 and 2020. For outcome and toxicity endpoints, we used Kaplan-Meier survival curves and the chi-square test for univariate analysis.
resultsThe median time from RP to m-HRT was 11 months (interquartile [IQR], 8.3-31.4). The median total dose to the prostate bed was 69.75 Gy (IQR, 65.25-72 Gy) (2.25 Gy per fraction). With a median follow-up of 8.25 years (IQR 7.06-9.17 years), 10-year overall survival (OS), metastasis-free survival (MFS), and biochemical relapse-free survival (b-RFS) were 98.8% (95% CI, 95.4-99.7), 85.9% (95% CI, 79.7-90.3), and 82.4% (95% CI, 75.8-87.3), respectively. Late genitourinary (GU) toxicity of grade ≥ 2 was observed in 14 (8.1%) patients. The 10-year freedom from late grade ≥ 2 GU toxicity was 89.8% (95% CI, 83.2-93.8%). Late gastrointestinal (GI) toxicity grade ≥ 2 was reported in 2 (1.1%) patients. The 10-year freedom from late grade ≥ 2 GI toxicity was 98.8% (95% CI, 95.3-99.7%). At univariate analysis, acute GU toxicity was associated with late GU toxicity (p = 0.016).
conclusionsOur long-term results confirm the critical role of modern radiotherapy in curing PCa in the post-operative setting, reducing overall treatment time and the risk of toxicity.
Indexed as
Identifiers
41942796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.